Adverse events
ADVERSE EVENTS
Serious adverse events (grade 3 and 4 according to CTCAE 4.0) were observed in 13 patients in the control group (13/41, 32%) and in 13 patients in the intervention group (13/37, 35%) with no difference between the two arms (